The 30 leading pharmaceutical companies of Japan accounted for combined healthcare revenue of $91.79 billion for fiscal 2009. This amount represented an almost 4% increase compared with the fiscal 2008 healthcare revenue for the same companies. Including all business segments, total fiscal 2009 revenue for the 30 entities came to $218.58 billion. The combined healthcare R&D expenditure for these corporations during fiscal 2009 amounted to about the same figure as compared with the previous year.
The following information is included for the Top 30 Japanese companies, which were determined based on their healthcare revenue generated during 2009:
- Each pipeline products’ chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer
- Pipeline status details preclinical development, Phase I, Phase II, Phase III, and awaiting approval
- Region of development includes the U.S., Europe, and Japan
- Select 2009 and 2008 financial data such as revenue, net income, earnings per share, and R&D expenditure
The report overview includes news updates and overall status for the leading Japanese companies. The analysis details promising pipeline candidates, the R&D structure of each corporation, as well company management plans and goals.